Adiponectin and Insulin Resistance in Diabetic Nephropathy

Plasma adiponectin concentration is inversely associated with renal function. There is little literature on adiponectin levels and regulation by antihypertensive medication with an angiotensin II-receptor blocker (ARB), especially in subjects with type 2 diabetes in different stage of chronic kidney disease (CKD).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetic Nephropathy Diabetes Complications Diabetes Mellitus Diabetes Mellitus, Type 2 Diabetic Nephropathies Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Glucose Metabolism Disorders Kidney Diseases Male Urogenital Diseases Metabolic Diseases Nutritional and Metabolic Diseases Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Shanghai No.3 people's hospital

Shanghai, 201900, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Type 2 diabetic nephropathy
CKD at stage 1~4

Exclusion criteria

Type 1 diabetes or nondiabetic renal disease
An elevated plasma K level.

Treatment and study plan

Losartan

Drug

Angiotensin II Type 1 Receptor Blockers

Primary outcomes

GFR, HbA1c and the adiponectin concentration

Time frame: 6 month

Sponsors and collaborators

Lead sponsor

Xi'an Jiaotong University

Other

Collaborators

Shanghai Jiao Tong University School of Medicine

Registry information

Official study title

Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan

Important dates

Study start: 2007
Primary completion: 2007
Study completion: 2007
First posted: Oct 17, 2008
Registry last updated: Oct 20, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed